Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus

References

• Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care26(3), 917–932 (2003).
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care29(6), 1263–1268 (2006).
   PubMed Web of Science ®Google Scholar
• Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey,1988–1994. Diabetes Care21(4), 518–524 (1998).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Movahed M-R, Hashemzadeh M, Mazen Jamal M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int. J. Cardiol.105(3), 315–318 (2005).
   PubMed Web of Science ®Google Scholar
• Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev.25(4), 543–567 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 Guidelines for the evaluation and management of heart failure). J. Am. Coll. Cardiol.46(6), 1116–1143 (2005).
   Web of Science ®Google Scholar
• Ikeda T, Matsuda K, Itoh H et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am. Heart J.133(3), 307–314 (1997).
   PubMed Web of Science ®Google Scholar
• Vanderheyden M, Goethals M, Verstreken S et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J. Am. Coll. Cardiol.44(12), 2349–2354 (2004).
   PubMed Web of Science ®Google Scholar
• Iwanaga Y, Nishi I, Furuichi S et al. B-Type Natriuretic Peptide Strongly Reflects Diastolic Wall Stress in Patients With Chronic Heart Failure: Comparison Between Systolic and Diastolic Heart Failure. J. Am. Coll. Cardiol.47(4), 742–748 (2006).
   PubMed Web of Science ®Google Scholar
• Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol.44(4), 740–749 (2004).
   Google Scholar
• Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin.l Endocrinol.47(3), 287–296 (1997).
   PubMed Web of Science ®Google Scholar
• Yano Y, Katsuki A, Gabazza EC et al. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab.84(7), 2353–2356 (1999).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation109(5), 594–600 (2004).
   PubMed Web of Science ®Google Scholar
• Das SR, Drazner MH, Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation112(14), 2163–2168 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am. Heart J.152(6), 1071–1076 (2006).
   PubMed Web of Science ®Google Scholar
• Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care27(8), 1929–1935 (2004).
   PubMed Web of Science ®Google Scholar
• Bhalla MA, Chiang A, Epshteyn VA et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J. Am. Coll. Cardiol.44(5), 1047–1052 (2004).
   PubMed Web of Science ®Google Scholar
• Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia48(1), 156–163 (2005).
   PubMed Web of Science ®Google Scholar
• Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia48(1), 149–155 (2005).
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Timmer JR et al. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am. J. Cardiol.97(2), 167–172 (2006).
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gustafsson I, Omland T et al. Prognostic value of NH2-terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care29(6), 1411–1413 (2006).
   Google Scholar
• Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia49(10), 2256–2262 (2006).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA241(19), 2035–2038 (1979).
   PubMed Web of Science ®Google Scholar
• Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes23(2), 105–111 (1974).
   Google Scholar
• Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care20(6), 935 (1997).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Furberg CD, Kuller LH et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch. Intern. Med.159(12), 1339–1347 (1999).
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation106(25), 3143 (2002).
   PubMed Web of Science ®Google Scholar
• Cohn PF, Fox KM, Daly C. Silent Myocardial Ischemia. Circulation108(10), 1263–1277 (2003).
   PubMed Web of Science ®Google Scholar
• Froelicher VF, Thomas MM, Pillow C, Lancaster MC. Epidemiologic study of asymptomatic men screened by maximal treadmill testing for latent coronary artery disease. Am. J. Cardiol.34(7), 770–776 (1974).
   PubMedGoogle Scholar
• Fazzini PF, Prati PL, Rovelli F et al. Epidemiology of silent myocardial ischemia in asymptomatic middle-aged men (the ECCIS Project). Am. J. Cardiol.72(18), 1383–1388 (1993).
   PubMed Web of Science ®Google Scholar
• Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. Br. Med. J.301(6743), 92–94 (1990).
   PubMed Web of Science ®Google Scholar
• Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am. J. Cardiol.79(2), 134–139 (1997).
   PubMed Web of Science ®Google Scholar
• Lubaszewski W, Kawecka-Jaszcz K, Czarnecka D, Rajzer M, Stochmal A. Silent myocardial ischaemia in patients with essential arterial hypertension and non-insulin dependent diabetes mellitus. J. Hum. Hypertens.13(5), 309 (1999).
   Google Scholar
• Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care22(9), 1396–1400 (1999).
   PubMed Web of Science ®Google Scholar
• Bacci S, Villella M, Villella A et al. Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur. J. Endocrinol.147(5), 649–654 (2002).
   PubMed Web of Science ®Google Scholar
• Gazzaruso C, Garzaniti A, Giordanetti S et al. Assessment of Asymptomatic coronary artery disease in apparently uncomplicated Type 2 Diabetic Patients: A role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care25(8), 1418–1424 (2002).
   Google Scholar
• Fornengo P, Bosio A, Epifani G, Pallisco O, Mancuso A, Pascale C. Prevalence of silent myocardial ischaemia in new-onset middle-aged type 2 diabetic patients without other cardiovascular risk factors. Diabet. Med.23(7), 775–779 (2006).
   PubMedGoogle Scholar
• Wackers FJT, Young LH, Inzucchi SE et al. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD study. Diabetes Care27(8), 1954–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Lee DP, Fearon WF, Froelicher VF. Clinical utility of the exercise ECG in patients with diabetes and chest pain. Chest119(5), 1576–1581 (2001).
   Google Scholar
• Rana BS, Davies JI, Band MM, Pringle SD, Morris A, Struthers AD. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart92(7), 916–920 (2006).
   PubMed Web of Science ®Google Scholar
• Rutter MK, Wahid ST, McComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J. Am. Coll. Cardiol.40(1), 56–61 (2002).
   PubMed Web of Science ®Google Scholar
• Faglia E, Favales F, Calia P et al. Cardiac Events in 735 Type 2 Diabetic Patients Who Underwent Screening for Unknown Asymptomatic Coronary Heart Disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care25(11), 2032–2036 (2002).
   Google Scholar
• Faglia E, Manuela M, Antonella Q et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am. Heart J.149(2), e1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am. J. Cardiol.34(1), 29–34 (1974).
   PubMed Web of Science ®Google Scholar
• Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol.30(6), 595–602 (1972).
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr.18(12), 1440–1463 (2005).
   PubMed Web of Science ®Google Scholar
• Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am. J. Cardiol.68(1), 85–89 (1991).
   PubMed Web of Science ®Google Scholar
• Lee M, Gardin JM, Lynch JC et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study. Am. Heart J.133(1), 36–43 (1997).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function : The Strong Heart Study. Circulation101(19), 2271–2276 (2000).
   PubMed Web of Science ®Google Scholar
• Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: The Casale Monferrato Study. Diabet. Med.21(8), 823–828 (2004).
   Google Scholar
• Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH. Screening for heart disease in diabetic subjects. Am. Heart J.149(2), 349–354 (2005).
   PubMed Web of Science ®Google Scholar
• Sato A, Tarnow L, Nielsen FS, Knudsen E, Parving HH. Left ventricular hypertrophy in normoalbuminuric Type 2 diabetic patients not taking antihypertensive treatment. QJM98(12), 879–884 (2005).
   Google Scholar
• Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia48(10), 1971–1979 (2005).
   PubMed Web of Science ®Google Scholar
• Palmieri V, Tracy RP, Roman MJ et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the Strong Heart Study. Diabetes Care26(10), 2764–2769 (2003).
   PubMedGoogle Scholar
• Blackburn H. Classification of the electrocardiogram for population studies: Minnesota code. J. Electrocardiol.2(3), 305–310 (1969).
   PubMedGoogle Scholar
• Lewis T. Observations upon ventricular hypertrophy, with special reference to preponderance of one or another chamber. Heart5, 367–403 (1914).
   Google Scholar
• Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart J.37(2), 161–186 (1949).
   PubMed Web of Science ®Google Scholar
• Casale PN, Devereux RB, Kligfield P et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J. Am. Coll. Cardiol.6(3), 572–580 (1985).
   PubMed Web of Science ®Google Scholar
• Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation75(3), 565–572 (1987).
   PubMed Web of Science ®Google Scholar
• Norman JE Jr, Levy D, Campbell G, Bailey JJ. Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm. J. Am. Coll. Cardiol.21(7), 1680–1686 (1993).
   PubMedGoogle Scholar
• Gubner R, Ungerleider HE. Electrocardiographic criteria of left ventricular hypertrophy. Factors determining the evolution of the electrocardiographic pattern in hypertrophy and bundle branch block. Arch. Intern. Med.72, 196–209 (1943).
   Google Scholar
• Siegel RJ, Roberts WC. Electrocardiographic observations in severe aortic valve stenosis: Correlative necropsy study to clinical, hemodynamic, and ECG variables demonstrating relation of 12-lead QRS amplitude to peak systolic transaortic pressure gradient. Am. Heart J.103(2), 210–221 (1982).
   Web of Science ®Google Scholar
• Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J. Am. Coll. Cardiol.20(5), 1180–1186 (1992).
   PubMed Web of Science ®Google Scholar
• Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation81(3), 815–820 (1990).
   PubMed Web of Science ®Google Scholar
• Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am. Heart J.75(6), 752–758 (1968).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J. Am. Coll. Cardiol.31(2), 383–390 (1998).
   PubMed Web of Science ®Google Scholar
• Rautaharju PM, LaCroix AZ, Savage DD et al. Electrocardiographic estimate of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the epidemiologic follow-up study of the First National Health and Nutrition Examination Survey. Am. J. Cardiol.62(1), 59–66 (1988).
   PubMed Web of Science ®Google Scholar
• de Vries SO, Heesen WF, Beltman FW et al. Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension. Am. J. Cardiol.77(11), 974–978 (1996).
   PubMed Web of Science ®Google Scholar
• Wolf HK, Burggraf GW, Cuddy E et al. Prediction of left ventricular mass from the electrocardiogram. J. Electrocardiol.24(2), 121–127 (1991).
   Google Scholar
• Dahlöf B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am. J. Hypertens.10(7 Pt 1), 705–713 (1997).
   PubMed Web of Science ®Google Scholar
• Hsieh BP, Pham MX, Froelicher VF. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. Am. Heart J.150(1), 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Romhilt DW, Bove KE, Norris RJ et al. A critical appraisal of the electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. Circulation40(2), 185–195 (1969).
   PubMed Web of Science ®Google Scholar
• Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J. Am. Coll. Cardiol.25(2), 417–423 (1995).
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Eriksson S et al. Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. Clin. Physiol.21(2), 196–207 (2001).
   Google Scholar
• Wachtell K, Smith G, Gerdts E et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am. J. Cardiol.85(4), 466–472 (2000).
   PubMed Web of Science ®Google Scholar
• Mayet J, Shahi M, McGrath K et al. Left Ventricular Hypertrophy and QT Dispersion in Hypertension. Hypertension28(5), 791–796 (1996).
   PubMed Web of Science ®Google Scholar
• Oikarinen La, Nieminen MSa, Viitasalo Ma et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. J. Hypertens.19(10), 1883–1891 (2001).
   PubMed Web of Science ®Google Scholar
• Chapman N, Mayet J, Ozkor M, Lampe FC, Thom SAM, Poulter NR. QT intervals and QT dispersion as measures of left ventricular hypertrophy in an unselected hypertensive population. Am. J. Hypertens.14(5), 455–462 (2001).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CRL, Deccache W. Multivariate associates of QT interval parameters in diabetic patients with arterial hypertension: importance of left ventricular mass and geometric patterns. J. Hum. Hypertens.17(8), 561 (2003).
   Google Scholar
• Salles G, Leocadio S, Bloch K, Nogueira AR, Muxfeldt E. Combined QT interval and voltage criteria improve left ventricular hypertrophy detection in resistant hypertension. Hypertension46(5), 1207–1212 (2005).
   PubMed Web of Science ®Google Scholar
• Abergel E, Tase M, Menard J, Chatellier G. Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am. J. Cardiol.77(9), 739–744 (1996).
   PubMed Web of Science ®Google Scholar
• Okin PM, Roman MJ, Devereux RB, Kligfield P. ECG identification of left ventricular hypertrophy: Relationship of test performance to body habitus. J. Electrocardiol.29(Suppl. 1), 256–261 (1996).
   PubMed Web of Science ®Google Scholar
• Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B, Group FT. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension35(1 Pt 1), 13–18 (2000).
   Google Scholar
• Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation55(4), 613–618 (1977).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol.57(6), 450–458 (1986).
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr.2(5), 358–367 (1989).
   PubMed Web of Science ®Google Scholar
• Reichek N, Helak J, Plappert T, Sutton MS, Weber KT. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation67(2), 348–352 (1983).
   PubMed Web of Science ®Google Scholar
• Byrd BF 3rd, Finkbeiner W, Bouchard A, Silverman NH, Schiller NB. Accuracy and reproducibility of clinically acquired two-dimensional echocardiographic mass measurements. Am. Heart J.118(1), 133–137 (1989).
   Google Scholar
• Gopal AS, Schnellbaecher MJ, Shen Z, Akinboboye OO, Sapin PM, King DL. Freehand three-dimensional echocardiography for measurement of left ventricular mass: in vivo anatomic validation using explanted human hearts. J. Am. Coll. Cardiol.30(3), 802–810 (1997).
   Google Scholar
• Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension39(3), 750–755 (2002).
   PubMed Web of Science ®Google Scholar
• Alfakih K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J. Hypertens.24(7), 1223–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Katz J, Milliken MC, Stray-Gundersen J et al. Estimation of human myocardial mass with MR imaging. Radiology169(2), 495–498 (1988).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am. J. Hypertens.16(12), 1025–1029 (2003).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA288(10), 1252–1259 (2002).
   PubMed Web of Science ®Google Scholar
• Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet359(9315), 1430–1432 (2002).
   PubMed Web of Science ®Google Scholar
• Dawson A, Davies JI, Morris AD, Struthers AD. B-type natriuretic Peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. Am. J. Hypertens.18(12 Pt 1), 1586–1591 (2005).
   Google Scholar
• Andersen NH, Poulsen SH, Knudsen ST, Heickendorff L, Mogensen CE. NT-proBNP in normoalbuminuric patients with Type 2 diabetes mellitus. Diabet. Med.22(2), 188–195 (2005).
   Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med.322(22), 1561–1566 (1990).
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham heart study. J. Am. Coll. Cardiol.25(4), 879–884 (1995).
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation103(19), 2346–2351 (2001).
   PubMed Web of Science ®Google Scholar
• Okin PM, Roman MJ, Lee ET, Galloway JM, Howard BV, Devereux RB. Combined echocardiographic left ventricular hypertrophy and electrocardiographic ST depression improve prediction of mortality in American Indians: the Strong Heart Study. Hypertension43(4), 769–774 (2004).
   PubMed Web of Science ®Google Scholar
• Casale PN, Devereux RB, Milner M et al. Value of Echocardiographic Measurement of Left Ventricular Mass in Predicting Cardiovascular Morbid Events in Hypertensive Men. Ann. Intern. Med.105(2), 173–178 (1986).
   PubMed Web of Science ®Google Scholar
• Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med.114(5), 345–352 (1991).
   PubMed Web of Science ®Google Scholar
• Lonn E, Mathew J, Pogue J et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur. J. Cardiovasc. Prev. Rehabil.10(6), 420–428 (2003).
   PubMedGoogle Scholar
• Behar S, Reicher-Reiss H, Abinader E et al. Long-term prognosis after acute myocardial infarction in patients with left ventricular hypertrophy on the electrocardiogram. SPRINT Study Group. Am. J. Cardiol.69(12), 985–990 (1992).
   Google Scholar
• Yotsukura M, Suzuki J, Yamaguchi T et al. Prognosis following acute myocardial infarction in patients with ECG evidence of left ventricular hypertrophy prior to infarction. J. Electrocardiol.31(2), 91–99 (1998).
   Google Scholar
• Goldenberg I, Matetzky S, Hod H, Behar S, Freimark D. Outcome of patients with electrocardiographic evidence of left ventricular hypertrophy following thrombolytic therapy for acute myocardial infarction. Am. J. Cardiol.88(9), 1024–1026 (2001).
   Google Scholar
• Quinones MA, Greenberg BH, Kopelen HA et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol.35(5), 1237–1244 (2000).
   Web of Science ®Google Scholar
• Lopez-Gomez JM, Verde E, Perez-Garcia R. Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int.68(Suppl.), S92–S98 (1998).
   Google Scholar
• Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation102(4), 470–479 (2000).
   PubMed Web of Science ®Google Scholar
• Boner G, Cooper ME, McCarroll K et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia48(10), 1980–1987 (2005).
   PubMedGoogle Scholar
• Milani RV, Lavie CJ, Mehra MR, Ventura HO, Kurtz JD, Messerli FH. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am. J. Cardiol.97(7), 959–963 (2006).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J. Am. Coll. Cardiol.25(4), 871–878 (1995).
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, Lapenna D, Bucci A, Manente BM, Cuccurullo F, Mezzetti A. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am. J. Hypertens.17(11 Pt 1), 1035–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med.115(1), 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Hinderliter A, Sherwood A, Gullette ECD et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch. Intern. Med.162(12), 1333–1339 (2002).
   PubMedGoogle Scholar
• Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens.16(11 Pt 1), 895–899 (2003).
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA292(19), 2350–2356 (2004).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Gerdts E et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation113(12), 1588–1596 (2006).
   PubMedGoogle Scholar
• Havranek EP, Esler A, Estacio RO, Mehler PS, Schrier RW. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am. Heart J.145(6), 993–998 (2003).
   PubMed Web of Science ®Google Scholar
• Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care24(1), 5–10 (2001).
   PubMed Web of Science ®Google Scholar
• Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am. J. Cardiol.87(3), 320–323 (2001).
   PubMed Web of Science ®Google Scholar
• Liu JE, Robbins DC, Palmieri V et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study. J. Am. Coll. Cardiol.41(11), 2022–2028 (2003).
   PubMed Web of Science ®Google Scholar
• Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am. J. Cardiol.93(7), 870–875 (2004).
   PubMed Web of Science ®Google Scholar
• Valle R, Bagolin E, Canali C et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur. J. Echocardiogr.7(1), 40–44 (2006).
   PubMed Web of Science ®Google Scholar
• Nicolino A, Longobardi G, Furgi G et al. Left ventricular diastolic filling in diabetes mellitus with and without hypertension. Am. J. Hypertens.8(4 Pt 1), 382–389 (1995).
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part II. Clinical studies. Mayo Clin. Proc.64(2), 181–204 (1989).
   PubMed Web of Science ®Google Scholar
• Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using doppler echocardiography. J. Am. Coll. Cardiol.27(7), 1753–1760 (1996).
   PubMed Web of Science ®Google Scholar
• Nishimura RA, Tajik AJ. Evaluation of Diastolic Filling of Left Ventricle in Health and Disease: Doppler Echocardiography Is the Clinician’s Rosetta Stone. J. Am. Coll. Cardiol.30(1), 8–18 (1997).
   PubMed Web of Science ®Google Scholar
• Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J. Am. Soc. Echocardiogr.10(3), 246–270 (1997).
   PubMed Web of Science ®Google Scholar
• Choong CY, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J. Am. Coll. Cardiol.10(4), 800–808 (1987).
   PubMed Web of Science ®Google Scholar
• Dumesnil JG, Gaudreault G, Honos GN, Kingma JG Jr. Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension. Am. J. Cardiol.68(5), 515–519 (1991).
   PubMed Web of Science ®Google Scholar
• Hurrell DG, Nishimura RA, Ilstrup DM, Appleton CP. Utility of Preload Alteration in Assessment of Left Ventricular Filling Pressure by Doppler Echocardiography: A Simultaneous Catheterization and Doppler Echocardiographic Study. J. Am. Coll. Cardiol.30(2), 459–467 (1997).
   PubMed Web of Science ®Google Scholar
• Whalley GA, Walsh HJ, Gamble GD, Doughty RN. Comparison of different methods for detection of diastolic filling abnormalities. J. Am. Soc. Echocardiogr.18(7), 710–717 (2005).
   Google Scholar
• Pozzoli M, Traversi E, Cioffi G, Stenner R, Sanarico M, Tavazzi L. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation95(5), 1222–1230 (1997).
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma Brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation109(25), 3176–3181 (2004).
   PubMed Web of Science ®Google Scholar
• Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation105(5), 595–601 (2002).
   PubMed Web of Science ®Google Scholar
• Epshteyn V, Morrison K, Krishnaswamy P et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care26(7), 2081–2087 (2003).
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Higa N, Oshiro Y, Asahi T, Takasu N. Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients. Diabetes Obes. Metab.9(3), 323–329 (2007).
   PubMed Web of Science ®Google Scholar
• Whalley GA, Gamble GD, Doughty RN. The prognostic significance of restrictive diastolic filling associated with heart failure: a meta-analysis. Int. J. Cardiol.116(1), 70–77 (2007).
   Google Scholar
• Whalley GA, Gamble GD, Doughty RN. Restrictive diastolic filling predicts death after acute myocardial infarction: systematic review and meta-analysis of prospective studies. Heart92(11), 1588–1594 (2006).
   Google Scholar
• Somaratne JB, Whalley GA, Gamble G, Doughty RN. Restrictive filling pattern is a powerful predictor of heart failure events post-acute myocardial infarction and in established heart failure: a literature-based meta-analysis. J. Card. Fail. (In press).
   Google Scholar
• Wang M, Yip GW, Wang AY et al. Tissue Doppler imaging provides incremental prognostic value in patients with systemic hypertension and left ventricular hypertrophy. J. Hypertens.23(1), 183–191 (2005).
   PubMed Web of Science ®Google Scholar
• Poirier P, Garneau C, Bogaty P et al. Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus. Am. J. Cardiol.85(4), 473–477 (2000).
   PubMedGoogle Scholar
• Saraiva RM, Duarte DM, Duarte MPC et al. Tissue Doppler imaging identifies asymptomatic normotensive diabetics with diastolic dysfunction and reduced exercise tolerance. Echocardiography22(7), 561–570 (2005).
   Google Scholar
• Fang ZY, Sharman J, Prins JB, Marwick TH. Determinants of exercise capacity in patients with Type II diabetes. Diabetes Care28(7), 1643–1648 (2005).
   PubMed Web of Science ®Google Scholar
• Janardhanan R, Daley WL, Naqvi TZ et al. Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. Am. Heart J.152(2), 246–252 (2006).
   Google Scholar
• Solomon SD, Janardhanan R, Verma A et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet, 369(9579), 2079–2087 (2007).
   PubMed Web of Science ®Google Scholar
• Beljic T, Miric M. Improved metabolic control does not reverse left ventricular filling abnormalities in newly diagnosed non-insulin-dependent diabetes patients. Acta Diabetol.31(3), 147–150 (1994).
   Google Scholar
• Gough SC, Smyllie J, Barker M, Berkin KE, Rice PJ, Grant PJ. Diastolic dysfunction is not related to changes in glycaemic control over 6 months in type 2 (non-insulin-dependent) diabetes mellitus. A cross-sectional study. Acta Diabetol.32(2), 110–115 (1995).
   Google Scholar
• Felicio JS, Ferreira SRG, Plavnik FL et al. Effect of blood glucose on left ventricular mass in patients with hypertension and Type 2 diabetes mellitus. Am. J. Hypertens.13(11), 1149–1154 (2000).
   Google Scholar
• ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia44(9), 1118–1120 (2001).
   PubMed Web of Science ®Google Scholar
• Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs64(5), 459–470 (2004).
   PubMed Web of Science ®Google Scholar
• Mustonen JN, Uusitupa MI, Laakso M et al. Left ventricular systolic function in middle-aged patients with diabetes mellitus. Am. J. Cardiol.73(16), 1202–1208 (1994).
   Google Scholar
• Vinereanu D, Nicolaides E, Tweddel AC et al. Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin. Sci.105(5), 591–599 (2003).
   PubMed Web of Science ®Google Scholar
• Fang ZY, Leano R, Marwick TH. Relationship between longitudinal and radial contractility in subclinical diabetic heart disease. Clin. Sci.106(1), 53–60 (2004).
   PubMed Web of Science ®Google Scholar
• Andersen NH, Poulsen SH, Eiskjaer H, Poulsen PL, Mogensen CE. Decreased left ventricular longitudinal contraction in normotensive and normoalbuminuric patients with Type II diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clin. Sci.105(1), 59–66 (2003).
   PubMed Web of Science ®Google Scholar
• Loimaala A, Groundstroem K, Majahalme S, Nenonen A, Vuori I. Impaired myocardial function in newly onset Type 2 diabetes associates with arterial stiffness. Eur. J. Echocardiogr.7(5), 341–347 (2006).
   Google Scholar
• Greenbaum RA, Ho SY, Gibson DG, Becker AE, Anderson RH. Left ventricular fibre architecture in man. Br. Heart J.45(3), 248–263 (1981).
   PubMedGoogle Scholar
• Boyle AJ, Kelly DJ, Zhang Y et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J. Mol. Cell Cardiol.39(2), 213–221 (2005).
   PubMed Web of Science ®Google Scholar
• Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am. Heart J.148(5), 883–888 (2004).
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med.327(10), 685–691 (1992).
   PubMed Web of Science ®Google Scholar
• Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet,361(9372), 1843–1848 (2003).
   PubMed Web of Science ®Google Scholar
• Andersen NH, Poulsen SH, Poulsen PL et al. Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clin. Sci. (Colch.)111(1), 53–59 (2006).
   Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes - 2007. Diabetes Care30(Suppl. 1), S4–41 (2007).
   PubMedGoogle Scholar